Skip to main content

Table 5 Ten-year risk of death in relation to Recurrence Score and tumor size and grade among ER-positive patients, stratified by treatment with tamoxifen

From: A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

Risk classifier

Cases

Controls

10-Year risk

   

%

95% CI

Tamoxifen treated

Recurrence Score (55 cases and 150 controls)

   Low (<18)

29%

63%

2.8

(1.7–3.9)

   Intermediate (18–30)

40%

23%

10.7

(6.3–14.9)

   High (≥31)

31%

13%

15.5

(7.6–22.8)

Tumor size (55 cases and 150 controls)

   ≤1 cm

16%

31%

3.6

(1.7–5.5)

   1.1–2 cm

44%

43%

5.8

(3.7–7.8)

   >2 cm

40%

26%

9.3

(5.5–13.1)

Tumor grade (55 cases and 150 controls)

   Well

11%

33%

2.1

(0.7–3.5)

   Moderate

51%

46%

6.9

(4.7–9.0)

   Poor

38%

21%

9.9

(6.0–13.7)

Tumor size and grade (55 cases and 150 controls)

   ≤2 cm and well or ≤1 cm and moderate

15%

43%

2.5

(1.2–3.9)

   >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor

49%

39%

7.2

(4.9–9.5)

   >2 cm and moderate/poor

36%

18%

11.5

(6.6–16.2)

Recurrence Score, tumor size and grade

   Recurrence Score low <18 (16 cases and 95 controls)

    

≤2 cm and well or ≤1 cm and moderate

6%

46%

0.4

(0.0–1.0)

>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor

63%

39%

4.1

(2.0–6.2)

>2 cm and moderate/poor

31%

15%

6.9

(1.8–11.7)

   Recurrence Score intermediate 18–30 (22 cases and 35 controls)

    

≤2 cm and well or ≤1 cm and moderate

32%

51%

6.8

(2.6–10.9)

>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor

45%

29%

21.9

(5.0–35.8)

>2 cm and moderate/poor

23%

20%

13.5

(1.2–24.2)

   Recurrence Score high ≥31 (17 cases and 20 controls)

    

≤2 cm and well or ≤1 cm and moderate

0%

10%

12.2

(0.0–31.0)

>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor

41%

60%

10.9

(2.9–18.3)

>2 cm and moderate/poor

59%

30%

28.9

(7.4–45.3)

Tamoxifen untreated

Recurrence Score (110 cases and 251 controls)

   Low (<18)

36%

64%

6.2

(4.5–7.9)

   Intermediate (18–30)

29%

19%

17.8

(11.8–23.3)

   High (≥31)

35%

18%

19.9

(14.2–25.2)

Tumor size (110 cases and 251 controls)

   ≤1 cm

29%

39%

8.5

(6.0–10.9)

   1.1–2 cm

41%

45%

10.4

(7.8–12.9)

   >2 cm

30%

16%

16.4

(11.4–21.0)

Tumor grade (110 cases and 251 controls)

   Well

15%

33%

5.5

(3.4–7.4)

   Moderate

49%

52%

11.2

(8.6–13.8)

   Poor

35%

15%

22.5

(15.9–28.6)

Tumor size and grade (110 cases and 251 controls)

   ≤2 cm and well or ≤1 cm and moderate

27%

50%

6.2

(4.3–8.0)

   >2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor

45%

37%

14.2

(10.8–17.4)

   >2 cm and moderate/poor

27%

13%

19.1

(13.2–24.7)

Recurrence Score, tumor size and grade

   Recurrence Score low <18 (40 cases and 160 controls)

    

≤2 cm and well or ≤1 cm and moderate

35%

63%

3.0

(1.7–4.3)

>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor

48%

31%

11.0

(7.0–14.8)

>2 cm and moderate/poor

17%

6%

20.2

(6.1–32.2)

   Recurrence Score intermediate 18–30 (32 cases and 47 controls)

    

≤2 cm and well or ≤1 cm and moderate

34%

38%

17.0

(8.2–24.9)

>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor

38%

34%

20.9

(10.2–30.4)

>2 cm and moderate/poor

28%

28%

22.0

(9.3–32.9)

   Recurrence Score high ≥31 (38 cases and 44 controls)

    

≤2 cm and well or ≤1 cm and moderate

13%

14%

25.0

(7.9–39.0)

>2 cm and well, or 1.1–2 cm and moderate, or ≤2 cm and poor

50%

59%

21.0

(13.8–27.5)

>2 cm and moderate/poor

37%

27%

25.3

(15.1–34.3)

  1. CI, confidence interval; ER, estrogen receptor.